Article

Valeant unveils Allergan merger proposal

Valeant Pharmaceuticals has proposed a merger with Allergan.

Valeant Pharmaceuticals has proposed a merger with Allergan.

Allergan’s largest shareholder (9.7%), Pershing Square Capital Management-managed by Bill Ackman- said he supports the initiative, according to Bloomberg. Additionally, Ackman said he believes that Allergan is undervalued and worked with Valeant to cooperatively engage in a hostile takeover of Allergan.

According to the Wall Street Journal, Valeant offered Allergan $48.30 and 0.83 Valeant shares per Allergan share.

Allergan’s stock price was $116.63 on April 10, the day before Ackman began rapidly accumulating shares. It increased to $166.41 after news broke of Valeant’s interest.

Valeant finalized its acquisition of Bausch + Lomb in August 2013.

Newsletter

Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.

Related Videos
(Image credit: Ophthalmology Times) Dilsher Dhoot, MD, on the evolution of geographic atrophy therapy: where are we now?
(Image credit: Ophthalmology Times Europe) Anat Loewenstein, MD, shares insights on the real-world results of remote retinal imaging
(Image credit: Ophthalmology Times) Two-wavelength autofluorescence for macular xanthophyll carotenoids with Christine Curcio, PhD
(Image credit: Ophthalmology Times) FLIO and the brain: Making the invisible visible with Robert Sergott, MD
(Image credit: Ophthalmology Times) Structure-function correlates using high-res OCT images with Karl Csaky, MD, PhD
(Image credit: Ophthalmology Times) SriniVas Sadda, MD, on high-res OCT of atrophic and precursor lesions in AMD
(Image credit: Ophthalmology Times) Christine Curcio, PhD, shares histology update supporting review software and revised nomenclature for <3 μm OCT
1 expert is featured in this series.
1 expert is featured in this series.
© 2025 MJH Life Sciences

All rights reserved.